‍Paris, October 2025 — Over the past year, Antibiogo has reached two important milestones confirming its growing impact as a safe, reliable, and high-quality diagnostic tool supporting the fight against antimicrobial resistance (AMR) in low — and middle — income countries (LMICs).

Recognized by WHO as an Innovative Health Technology

In 2024, Antibiogo was featured in the World Health Organization’s Compendium of Innovative Health Technologies for Low-Resource Settings (pages 56-58).
This recognition highlights Antibiogo as an innovative and clinically recommended tool that strengthens bacterial infection diagnosis and promotes rational antibiotic use in LMICs.

According to the WHO report, Antibiogo is:

“A stand-alone software application that assists laboratory technicians in measuring inhibition zone diameters and interpreting antibiotic susceptibility tests (AST)… particularly useful in laboratories where professionals may not have specific microbiology training, especially in resource-limited LMICs.”

The Compendium also notes Antibiogo’s Technology Readiness Level of 9, confirming its maturity and strong potential to reduce the burden of AMR by improving diagnostic access and quality.

Antibiogo is a free, offline-capable mobile application that enables laboratory technicians to interpret AST results directly from a smartphone. It includes training materials and user support, making it especially suitable for facilities lacking automated readers or clinical microbiologists.
Its inclusion in the WHO Compendium recognizes the value of such accessible, field-tested digital tools in strengthening health systems.

A Quality Milestone: ISO 13485 Certification

In 2025, Antibiogo’s Quality Management System earned ISO 13485 certification, marking a major step forward in ensuring the safety, consistency, and reliability of its design and development processes.

As Julien Dupont, Antibiogo’s Quality Lead, explains in a recent interview, achieving ISO 13485 certification proves that every step — from design to post-market monitoring — meets international standards for medical devices. This is a key step to ensure that Antibiogo remains a safe and trustworthy tool for all users.

This achievement is a first for a non-governmental initiative in this field, showing that humanitarian-driven innovations can meet the same rigorous quality standards as commercial medical devices while maintaining accessibility and equity: this reinforces Antibiogo’s commitment ensuring that innovation for low-resource settings is not only effective but also safe and compliant with international regulations.

A Step Forward for Accessible and Reliable Diagnostics

These two milestones mark a turning point for Antibiogo’s mission: providing safe, high-quality, and accessible diagnostic tools to healthcare professionals in low-resource settings.

As Nada Malou from the Antibiogo team notes: “Antibiogo’s journey shows that impactful innovation can come from the field. We now look forward to working hand in hand with health authorities and partners to make this tool available to all who need it.”

Together, we can:

• Strengthen microbiology diagnostic and surveillance capacity,
• Improve the quality and consistency of AST results,
• And support rational antibiotic use at all levels of care.

Starting a new phase of collaboration and scale-up, Antibiogo invites Ministries of Health, public laboratories, and international partners to collaborate in integrating the tool into national AMR strategies and laboratory systems.